Investors

Press Releases

Press Releases

September 19, 2022
SAN CARLOS, Calif. , Sept. 19, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced the pricing of an underwritten offering of 29,882,000 shares of its common
Displaying 1 - 10 of 11

Data Provided by Refinitiv. Minimum 15 minutes delayed.